Used primarily in the treatment of mild to moderate ulcerative colitis, this compound acts as an anti-inflammatory agent delivered specifically to the colon. It releases its active moiety, 5-aminosalicylic acid (5-ASA), upon bacterial cleavage in the large intestine, minimizing systemic absorption and reducing inflammation locally. This targeted action helps induce and maintain remission in patients with active disease, particularly in the distal regions of the colon. It is often preferred for its favorable safety profile and reduced incidence of upper gastrointestinal side effects compared to other oral aminosalicylates.